Skip to content

    PI Industries Q1 FY27 earnings call

    PIIND
    Chemicals·12 Aug 2026
    Management Summary

    PI Industries reported a revenue of ₹17,023 million for Q1 FY27 with a strong 57% gross margin and 22% EBITDA margin. The domestic business showed robust 12% volume growth, and biologicals grew 50%. While the global and domestic agrochemical markets faced headwinds and pricing pressure, the company continues to invest significantly in R&D and new growth platforms like Pharma and Biologicals, leading to short-term subsidiary losses but positioning for long-term growth.

    Highlights

    7

    • Revenue of ₹17,023 million reported for Q1 FY27.

    • Gross margin maintained at a healthy 57% for the quarter.

    • EBITDA margin stood at 22%, translating to ₹3,693 million.

    • Domestic business achieved 12% volume growth and 3% revenue growth despite challenging conditions.

    • Biologicals segment showed aggressive growth of 50% in the quarter, with a 3-year CAGR of 15%.

    • Debt-free balance sheet with ₹38 billion in net cash provides resilience and flexibility for strategic investments.

    • Working capital reduction of 19 days, releasing ₹300 crore of cash.

    Concerns

    4

    • Global crop protection market remains challenging with soft commodity prices, muted recovery, geopolitical uncertainties, genericization pressures, and tariffs impacting exports.

    • Domestic market faced headwinds from El Nino, heatwaves, delayed sowing, and high prior-year inventories.

    • Pricing pressure observed in Agchem CSM and domestic agrochemical segments due to demand challenges and input costs.

    • Subsidiary businesses (Pharma and Global Biologicals) incurred approximately ₹100 crore EBITDA loss in Q1 FY27, reflecting significant upfront investments and long gestation periods.

    Key financials

    Single quarter

    10 metrics
    1. 01Revenue17,023 Mn
    2. 02Gross Margin57%
    3. 03EBITDA3,693 Mn
    4. 04EBITDA Margin22%
    5. 05Domestic Volume Growth12%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹250 crores this quarter · ₹700 crores (FY27) planned

    Debt

    Net ₹38 billion

    Liquidity

    Cash ₹38 billion

    Working capital reduction of 19 days released ₹300 crore of cash.

    Guidance & targets

    6
    CategoryTargetPriority
    Profitability
    Effective Tax Rate (ETR)
    around 24%
    		High
    Revenue
    FY27 Revenue Growth
    positive trajectory, lower single digit
    		Medium
    Outlook
    FY27 Performance
    better over FY26
    		High
    R&D
    R&D Investments as % of Revenue
    3% to 4%
    		High
    Product Launch
    Pioxaniliprole Domestic Launch
    early start this year
    		High
    Revenue Potential
    Dicloromezotiaz Revenue Potential
    three-digit product
    		Medium

    What to watch in Q2 FY27

    5

    Pioxaniliprole domestic launch

    within the year (FY27)
    CurrentAwaiting regulatory approvals
    TargetCommercial launch in India

    Why it matters

    Pioxaniliprole is a key new generation insecticide discovered in India, and its launch will demonstrate PI's innovation capabilities and contribute to domestic revenue.

    Hopefully💬, depending on the regulatory framework, we expect to have early start this year. We are hoping within the year we should get the launch for India.

    Risks & concerns

    5
    RiskSeverity

    Global crop protection market downturn

    Soft commodity prices, muted recovery in crop economics, geopolitical uncertainties, genericization pressures, and tariffs continue to exert pressure on growth and pricing for exports. — Management acknowledged

    medium

    Domestic market headwinds

    El Nino, strong heatwaves, delayed sowing, and high inventory levels from prior years have impacted pre-placement and sales of chemicals. — Management acknowledged

    medium

    Pricing pressure and margin contraction

    Demand challenges and high input costs are creating pressure on pricing and margins across the Agchem industry, requiring careful balance. — Management acknowledged

    medium

    Long gestation period and initial losses for new ventures

    Investments in Pharma (CRDMO) and Global Biologicals are significant and involve long gestation periods, leading to initial EBITDA losses (e.g., ~₹100 crore in Q1 FY27) as capabilities are built and markets developed. — Management acknowledged

    medium

    Volatility in early-stage CRDMO business

    The CRDMO business is in early stages with a small portfolio, leading to more volatility in revenues and delivery schedules, which is expected to reduce as the portfolio scales up. — Management acknowledged

    low

    Q&A highlights

    6

    “We are making investments in the regulatory framework, because the regulatory requirements need to be made upfront so that you are a part of that value chain as products progress, we are able to optimize. So usually the CRDMO in pharma is a long gestation J-curve. ...these are investments for development to scale up revenue and establish credibility of the product.”

    Analysts pressed on the timeline for subsidiary businesses (Pharma, Biologicals) to break even, given the current losses of ~₹100 crore in Q1 FY27, highlighting the long gestation period for these new ventures.

    asked by Riju, Siddharth Gadekar

    2 min read5 chapters

    Detailed Narrative

    01

    Global and Domestic Agrochemical Market Dynamics

    The global crop protection market is showing early signs of demand stabilization, but challenges persist due to soft commodity prices, geopolitical uncertainties, and genericization pressures. Domestically, Q1 FY27 was impacted by El Nino, heatwaves, and delayed sowing, leading to high inventories. Despite these headwinds, PI Industries' domestic business achieved a 12% volume growth and 3% revenue growth, while exports saw an 8% volume decline and 12% value decline. Management expects consumption patterns to see a positive trajectory ahead, with FY27 projected to be better than FY26, driven by export recovery in H2.

    02

    Strategic Investments in New Growth Platforms

    PI Industries is making significant investments in new high-value adjacencies, including Pharma, Electronic, and Specialty Chemicals, alongside expanding its Biologicals portfolio. The company has commissioned one of the world's largest flow plants, enhancing sustainable and cost-efficient production. In Pharma, PI is transitioning into a differentiated CRDMO organization, with early positive signs and a QC lab approved by regulators in Italy. These investments, particularly in Biologicals and Pharma, are leading to short-term EBITDA losses in subsidiaries (approx. ₹100 crore in Q1 FY27) but are considered essential for long-term value creation and scale.

    03

    Biologicals Segment Outperformance

    The Biologicals segment demonstrated strong performance, achieving 50% growth in Q1 FY27 and a 15% CAGR over the last three years. PI's unique foliar-applied nematicide, which can also be used as a seed or soil treatment, is gaining global traction. The nematicide market in Brazil alone is estimated at USD 750 million, and PI is targeting aggressive growth across Brazil, Mexico, Europe, and the US, supported by over 500 field trials and 1,000 grower engagements. The company aims for a double-digit market share in Brazil over the next 5-10 years.

    04

    Pioxaniliprole and New Product Pipeline

    PI Industries' first NCE, Pioxaniliprole, an insecticide discovered in India, is set for domestic launch soon, pending regulatory approvals, with global launches planned for next year and the year after. This product is a diamide with a differentiated approach, showing good potential in certain crops. Additionally, Dicloromezotiaz, a new generation product for diamondback moth, is also under launch this season, with a revenue potential to become a 'three-digit product' (in crores) in 5-7 years. The company's overall pipeline includes about 90 molecules, with 60% in advanced stages, primarily in Agchem, but also in Electronic Chemicals and Pharma.

    05

    Capital Allocation and Financial Health

    PI Industries maintains a strong, debt-free balance sheet with ₹38 billion in net cash, providing flexibility for strategic investments. The company spent ₹250 crore on capex in Q1 FY27, with a full-year guidance of ₹700-800 crore, allocated across existing manufacturing, new verticals, and innovation. A disciplined focus on working capital led to a 19-day reduction, releasing ₹300 crore in cash. The company's R&D investments, contributing 3-4% of revenue, are viewed as value creation for long-term sustainability and growth.

    This is an AI-generated summary of a publicly available earnings call transcript.